Form D · Pharmaceuticals
UCB S.A.
Smyrna, GA · CIK 0001290640
Offering snapshot reported May 13, 2015 · SEC filing
- Reported sold
- $788K Offering amount: $788K
- Investors reported
- 131 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 8, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 13, 2015 | Initial | $787,628 | No comparison | 131 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-239756
Source: Form D, filed May 13, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Kay Davies | Director |
| Albrecht De Graeve | Director |
| Arnoud De Pret | Director |
| Evelyn Du Monceau | Director |
| Ctesse Du Monceau De Bergendal | Executive |
| Harriet Edelman | Director |
| Charles Antoine Janssen | Director |
| Jean Pierre Kinet | Director |
| Gerhard Mayr | Director, Executive |
| Tom Mc Killop | Director |
| Norman Orstein | Director |
| Jean Christophe Tellier | Director, Executive |
| Cedric Van Rijckevorsel | Director |
| Jeffrey Wren | Executive |
| Michel Xavier | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
C/O Ucb, Inc. 1950 Lake Park Drive
Smyrna, GA, 30080
Smyrna, GA, 30080